Occurrence of CYP2B6 516G>T Polymorphism in Patients with ARV-associated Hepatotoxicity

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2019 Mar 14

PMID 30864294

Citations 1

Authors

HariOm Singh

Sonam Lata

T N Dhole

Raman R Gangakhedkar

Affiliations

Soon will be listed here.

Abstract

Background: Hepatic enzyme cytochrome P450 2B6 (CYP2B6) plays a role in the metabolism of efavirenz drugs. CYP2B6 516G>T variation showed an implication for HIV treatment.

Methods: CYP2B6 516G>T polymorphism was genotyped in a total 165 HIV patients that include 34 with and 131 without hepatotoxicity and 155 healthy individuals by the PCR-RFLP.

Results: In patients with hepatotoxicity, the prevalence of CYP2B6 516TT genotype was higher as compared to healthy individuals (35.3% vs. 30.5%, OR = 1.74). Patients with hepatotoxicity using tobacco had a higher prevalence of genotypes CYP2B6 516GT, 516TT, 516GT+TT as compared to healthy individuals (28.57% vs. 25.93%; 57.14% vs. 29.63%; 85.71% vs. 55.56%). Likewise, hepatotoxicity in patients consuming alcohol showed higher distributions of CYP2B6 516GT, 516TT, 516GT+TT genotypes (57% vs. 25.93%; 42.86% vs. 33.33%; 71.43% vs. 59.26%). Nevirapine users with hepatotoxicity overrepresented genotypes CYP2B6 TT and 516GT+TT as compared to efavirenz users (47.83% vs. 45.45%, OR = 6.88, 65.22% vs. 54.55%, OR = 1.56). Similarly, in nevirapine +alcohol users with hepatotoxicity, the frequency of CYP2B6 516GT, 516GT+TT genotypes was higher than with nevirapine +alcohol nonusers (40.0% vs. 11.11%, OR = 8.00, 80.0% vs. 27.78%, OR = 4.00). In HIV patients, nevirapine users had higher frequency of CYP2B6 516GT, 516GT+TT genotypes as compared to efavirenz users (42.02% vs. 25.00%, OR = 2.53; 72.27% vs. 58.33%, OR = 1.86). Likewise, in HIV patients, genotypes CYP2B6 516GT, 516GT+TT were predominant with nevirapine +alcohol users as compared to nevirapine +alcohol nonusers (57.89% vs. 34.57%, OR = 2.46; 78.95% vs. 69.14%, OR = 1.67). In multivariate logistic regression, taking nevirapine had a protection for severity of ARV-associated hepatotoxicity (OR = 0.23, p = 0.005).

Conclusions: No significant association was detected between CYP2B6 516G>T polymorphism and susceptibility to ARV-associated hepatotoxicity.

Citing Articles

Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity.

Singh H, Lata S, Dhole T, Gangakhedkar R Mol Genet Genomic Med. 2019; 7(4):e00598.

PMID: 30864294 PMC: 6465650. DOI: 10.1002/mgg3.598.

References

Watanabe T, Sakuyama K, Sasaki T, Ishii Y, Ishikawa M, Hirasawa N . Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenet Genomics. 2010; 20(7):459-62. DOI: 10.1097/FPC.0b013e32833bba0e. View

Servoss J, Kitch D, Andersen J, Reisler R, Chung R, Robbins G . Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr. 2006; 43(3):320-3. DOI: 10.1097/01.qai.0000243054.58074.59. View

Ramachandran G, Ramesh K, Kumar A, Jagan I, Vasantha M, Padmapriyadarsini C . Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother. 2009; 63(4):841-3. DOI: 10.1093/jac/dkp033. View

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M . Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother. 2011; 66(6):1332-9. PMC: 3092713. DOI: 10.1093/jac/dkr087. View

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett S . CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007; 21(16):2191-9. DOI: 10.1097/QAD.0b013e3282ef9695. View

Haas D, Smeaton L, Shafer R, Robbins G, Morse G, Labbe L . Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005; 192(11):1931-42. DOI: 10.1086/497610. View

Samet J, Cheng D, Libman H, Nunes D, Alperen J, Saitz R . Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2007; 46(2):194-9. PMC: 2247363. DOI: 10.1097/QAI.0b013e318142aabb. View

Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L . CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit. 2010; 32(5):573-8. DOI: 10.1097/FTD.0b013e3181ea953c. View

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer N . Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008; 61(4):914-8. PMC: 3596857. DOI: 10.1093/jac/dkn029. View

10.

Sadiq S, Fredericks S, Khoo S, Rice P, Holt D . Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS. 2005; 19(15):1716-7. DOI: 10.1097/01.aids.0000186828.99032.60. View

11.

Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V . Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005; 40(9):1358-61. DOI: 10.1086/429327. View

12.

Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L . Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007; 81(4):557-66. DOI: 10.1038/sj.clpt.6100072. View

13.

Ward B, Gorski J, Jones D, Hall S, Flockhart D, Desta Z . The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003; 306(1):287-300. DOI: 10.1124/jpet.103.049601. View

14.

Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy S, Kishikawa Y . Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 2002; 58(6):417-21. DOI: 10.1007/s00228-002-0499-5. View

15.

Singh H, Lata S, Dhole T, Gangakhedkar R . Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity. Mol Genet Genomic Med. 2019; 7(4):e00598. PMC: 6465650. DOI: 10.1002/mgg3.598. View

16.

Van Dyke R, Wang L, Williams P . Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008; 198(11):1599-608. PMC: 2737265. DOI: 10.1086/593022. View

17.

Tong K, He M, Lin C, Guo L, Kung H, Sung J . The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons. Clin Infect Dis. 2006; 43(4):541-2. DOI: 10.1086/505984. View

18.

Penzak S, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro R . Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 2007; 8(2):86-91. DOI: 10.1111/j.1468-1293.2007.00432.x. View

19.

Lindfelt T, OBrien J, Song J, Patel R, Winslow D . Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Ann Pharmacother. 2010; 44(10):1572-8. DOI: 10.1345/aph.1P141. View

20.

Haas D, Gebretsadik T, Mayo G, Menon U, Acosta E, Shintani A . Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis. 2009; 199(6):872-80. PMC: 2784690. DOI: 10.1086/597125. View